CL Item

Will The Participant Practice Adequate Birth Control To Prevent Pregnancy While Receiving Treatment And For Three Months After Treatment Is Discontinued (Will the participant practice adequate birth control to prevent pregnancy while receiving treatment and for three months after treatment is discontinued)

CL Item

Were The Following Laboratory Parameters Met And Performed Within 28 Days Prior To Study Entry: Hemoglobin (>= 8 G/dl); Anc (>= 1,000 Cells/mm^3); Platelet Count (>= 75,000/mm^3); Creatinine (< 1.5 X Uln); Ast (sgot) And Alt (sgpt) <= 3 X Uln (Were the following laboratory parameters met and performed within 28 days prior to study entry: Hemoglobin (>= 8 g/dl); ANC (>= 1,000 cells/mm^3); Platelet count (>= 75,000/mm^3); Creatinine (< 1.5 x ULN); AST (SGOT) and ALT (SGPT) <= 3 x ULN)

CL Item

Does (do) The Perianal Lesion(s) Have A Surface Area Of At Least 3 Square Centimeters (Does (Do) the perianal lesion(s) have a surface area of at least 3 square centimeters)

CL Item

Does The Participant Have A Biopsy-proven Perianal Hsil Within 12 Weeks Of Study Entry (Does the participant have a biopsy-proven perianal HSIL within 12 weeks of study entry)

CL Item

Date Of Biopsy (Date of biopsy)

CL Item

Does The Participant Have A Cd4 Count Of >200 (Does the participant have a CD4 count of >200)

CL Item

Does The Participant Want To Initiate Haart In The Next 12 Weeks (Does the participant want to initiate HAART in the next 12 weeks)

CL Item

Has The Participant Been On Stable Haart Therapy For At Least 12 Weeks Prior To Enrollment (Has the participant been on stable HAART therapy for at least 12 weeks prior to enrollment)

CL Item

Has The Participant Completely Healed From Treatment (Has the participant completely healed from treatment)

CL Item

Has The Participant Undergone Ablative/surgical Treatment Of Perianal Dysplasia (Has the participant undergone ablative/surgical treatment of perianal dysplasia)

CL Item

Has The Skin At The Site Of The Pretreatment Biopsy Re-epithelialized (Has the skin at the site of the pretreatment biopsy re-epithelialized)

CL Item

Is The Elevated Bilirubin Felt To Be Secondary To Indinavir Therapy (Is the elevated bilirubin felt to be secondary to Indinavir therapy)

CL Item

Is The Participant Currently Receiving Haart Therapy (Is the participant currently receiving HAART therapy)

CL Item

Is The Participant Receiving No Antiretroviral Therapy Or A Non-haart Antiretroviral Regimen (Is the participant receiving no antiretroviral therapy or a non-HAART antiretroviral regimen)

CL Item

Is The Total Bilirubin <= 1.5 X Uln (Is the total bilirubin <= 1.5 x ULN)

CL Item

Is Total Bilirubin <= 3.5 Mg/dl And Is Direct Bilirubin Normal (Is total bilirubin <= 3.5 mg/dl and is direct bilirubin normal)

CL Item

Karnofsky Performance Status (Karnofsky performance status)

CL Item

Has The Subject Received Topical Treatment For Perianal Dysplasia Within 4 Weeks Of Study Entry (Has the subject received topical treatment for perianal dysplasia within 4 weeks of study entry)

CL Item

Does The Participant Have Acute, Active Opportunistic Infection (other Than Oral Thrush, Yeast Vaginitis, Or Genital Herpes) Within The Last 14 Days (Does the participant have acute, active opportunistic infection (other than oral thrush, yeast vaginitis, or genital herpes) within the last 14 days)

CL Item

Is The Participant Receiving Acute Treatment For An Infection (other Than Oral Thrush, Yeast Vaginitis Or Genital Herpes) Or Other Serious Medical Illness Within 14 Days Of Study Entry (Is the participant receiving acute treatment for an infection (other than oral thrush, yeast vaginitis or genital herpes) or other serious medical illness within 14 days of study entry)